Bruce Goldman

Q&A with a Stanford addiction specialist on whether non-alcoholic beverages are helpful or harmful for those with alcohol use disorders

Statistics expert Julia Salzman returned to biology and has married her two areas of expertise to design a new form of genomics analysis.

The former chief of neuro-oncology at the Yale School of Medicine is a highly regarded scientist specializing in the study of brain tumors and an advocate of those underrepresented in medicine.

A few closely related drugs, all squarely aimed at treating Alzheimer’s disease, have served up what can be charitably described as a lackadaisical performance. Stanford Medicine neurologist Mike Greicius explains why these drugs, so promising in theory, don’t appear to be helping patients much if at all.

Stanford Medicine doctors and researchers are modifying existing chatbots to perform well in a frontier of AI-enhanced medicine: the doctor-patient interaction.

Researchers who study long COVID say its debilitating symptoms are often misdiagnosed by clinicians and dismissed by employers or loved ones because so little is known about the new syndrome.

An Ask Me Anything Q&A with Stanford Medicine's Sharon Chinthrahjah, and expert on all things allergy-related.

The goal of a decade-old program started by Stanford Medicine's Nilima Ragavan is to foster the sharing of lessons and evidence-based best practices between clinicians in the U.S. and India.

Paxlovid, effective in preventing severe COVID-19, didn’t appear to help long-COVID patients in this single-center study. But further research may show benefits with different doses or for people with specific symptoms.

The institute’s purpose is to understand the human immune system at multiple levels — molecular, genetic and cellular — and to harness this understanding to prevent and treat disease.